Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA

Executive Summary

From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.

You may also be interested in...



First Amendment Challenge To DTC Rule Unlikely From Industry; For Now, It Is 'Comply With Context'

DTC rule is a good fight to lose: it is a high-profile response to pricing, but will have a low impact – and is certainly a less painful solution than many of the alternatives.

DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its voluntary drug pricing disclosures program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

Related Content

Topics

UsernamePublicRestriction

Register

PS124070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel